Michael Bigham, Chairman and CEO at Paratek Pharmaceuticals, Inc. (PRTK), sold 5,000 shares at $15.05 ($75K) on 2017-02-06, disclosed to the SEC on 2017-02-08.
Scheduled sale ($75k) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.05 | 1,752 | $26K | 34.9% |
| 2 | $15.08 | 32 | $483 | 0.6% |
| 3 | $15.10 | 2,104 | $32K | 42.1% |
| 4 | $15.15 | 1,082 | $16K | 21.7% |
| 5 | $15.20 | 30 | $456 | 0.6% |
| Total | $15.09 avg | 5,000 |
| $75K |
| 100% |
| Filing → |
| PRTK | SELL | 2022-12-14 | $164K | — | Filing → |
| PRTK | SELL | 2022-11-01 | $21K | — | Filing → |
| PRTK | SELL | 2022-08-10 | $152K | — | Filing → |